Ureteral Cancer

The ureters are the two muscular tubes that transport urine from the kidneys to the bladder, each measuring roughly 25 to 30cm in length. Their inner lining consists of urothelial cells — the same epithelial cell type that lines the renal pelvis, the bladder, and the proximal urethra. Because the entire urinary tract shares this common lining, cancers arising in the ureter belong to the same biological family as bladder cancer and renal pelvis cancer, and patients with one urothelial malignancy carry an elevated risk of developing another at a different site along the tract.

Together, cancers of the renal pelvis and ureter are classified as Upper Tract Urothelial Carcinoma (UTUC). Ureteral tumors account for approximately one-third of UTUC cases, with the renal pelvis being the more commonly affected site. UTUC as a whole is uncommon, with an estimated incidence of one to two cases per 100,000 people annually. It is diagnosed most frequently in adults in their seventh and eighth decades and is two to three times more prevalent in men than in women. 

Ureteral cancer is often clinically silent in its early stages, and when symptoms do appear, they can closely mimic those of more common and less serious urinary tract conditions — a feature that frequently delays diagnosis.

Blood in the urine (hematuria)

• Blood in the urine is the presenting symptom in the majority of patients. It may be visible to the naked eye as pink, red, or dark-brown discoloration of the urine or microscopic, detectable only on urinalysis. A characteristic and clinically important feature is intermittency: the bleeding often appears, resolves spontaneously over days to weeks, and then recurs. This pattern can lead patients to attribute the initial episode to benign causes. Any unexplained hematuria in an adult, regardless of whether it resolves, warrants urological evaluation to exclude a urothelial malignancy.

Flank or back pain

• Flank or back pain develops when tumor growth obstructs urine drainage from the kidney, causing progressive distension of the renal collecting system (hydronephrosis). The resulting discomfort is typically dull and persistent, located in the ipsilateral flank. In some cases, passage of blood clots through the ureter produces episodes of colicky pain resembling renal stone disease.

Lower urinary tract symptoms

• Lower urinary tract symptoms — urinary urgency, frequency, and dysuria (painful urination) — may occur when the tumor involves the distal ureter in close proximity to the bladder.

Systemic features

• Systemic features including unexplained weight loss and deterioration in general well-being suggest locally advanced or metastatic disease.

Ureteral cancer develops when DNA damage accumulates within urothelial cells, impairing the normal regulatory mechanisms that govern cell proliferation and survival. These mutations lead to clonal expansion of abnormal cells, eventual invasion through the ureteral wall, and — if left untreated — regional and distant spread. In most patients, the initiating genetic events arise sporadically and cannot be attributed to a single identifiable cause.

Tobacco smoking

• Smoking is the single most important modifiable risk factor for ureteral cancer, as it is for all urothelial malignancies. Tobacco carcinogens are absorbed systemically, excreted in the urine, and concentrated along the urothelial surface — resulting in prolonged mucosal carcinogen exposure. The risk is dose-dependent and persists for years after cessation, though it diminishes progressively with time.
  
  

Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC)

• Lynch syndrome confers the highest hereditary risk of upper tract urothelial carcinoma. This autosomal dominant DNA mismatch repair deficiency syndrome increases the lifetime risk of UTUC by approximately 14-fold compared to the general population. Genetic testing is recommended for all patients with UTUC who are younger than 60 or who have a personal or family history consistent with Lynch syndrome.

Prior or concurrent bladder cancer

• Bladder cancer reflects the field cancerization of the entire urothelium. Approximately 2–4% of patients treated for bladder cancer subsequently develop UTUC, and conversely, patients diagnosed with UTUC have a 15–50% risk of developing bladder tumors over their lifetime.

Occupational carcinogen exposure 

• Prolonged contact with aromatic amines, benzidine, and related compounds in the rubber, dye, textile, and chemical manufacturing industries is associated with urothelial cancers throughout the urinary tract.

Analgesic nephropathy

• Long-term high-dose use of phenacetin-containing analgesics — compounds now largely withdrawn from most markets — has historically been linked to renal pelvic and ureteral cancers.

Smoking cessation is the most impactful preventive intervention for ureteral cancer. Absolute risk reduction is greatest when tobacco use is discontinued before the development of malignancy, but a meaningful benefit is observed at any stage of cessation.

Patients with confirmed Lynch syndrome should be enrolled in a structured surveillance program that includes periodic upper tract imaging and urine cytology, as recommended by their clinical team. Given that Lynch syndrome confers risk for multiple organ systems, multidisciplinary coordination between urological and gastroenterological or genetic medicine specialists is important.

Patients with a history of bladder cancer require surveillance of the upper urinary tracts at intervals specified by their treatment protocol, as the shared urothelial field places the entire tract at ongoing risk.